BTIG analyst David Larsen lowered the firm’s price target on Progyny (PGNY) to $30 from $35 but keeps a Buy rating on the shares after its Q4 earnings beat and below consensus guidance. The company delivered good growth excluding previously announced client transition, and the sell-off in the stock seems overdone, the analyst tells investors in a research note. The firm adds that on the call the management has highlighted that through Q1 member engagement has remained healthy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- INVO Fertility’s Wisconsin clinic joins Progyny network
- Progyny price target lowered to $28 from $34 at Truist
- Progyny price target lowered to $28 from $32 at KeyBanc
- Midday Fly By: Paramount wins Warner bidding, Amazon to invest $5oB in OpenAI
- Closing Bell Movers: Netflix up 10% after backing away from Warner deal